Craig Hallum Initiates Coverage on MediWound (NASDAQ:MDWD)

Research analysts at Craig Hallum started coverage on shares of MediWound (NASDAQ:MDWD) in a report issued on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $39.00 price target on the biopharmaceutical company’s stock. Craig Hallum’s price target suggests a potential upside of 134.94% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of MediWound in a research note on Friday, January 10th.

MediWound Trading Up 2.3 %

Shares of MediWound stock opened at $16.60 on Friday. The company has a 50 day moving average of $18.18 and a 200-day moving average of $17.71. MediWound has a 1-year low of $12.78 and a 1-year high of $24.00. The company has a market cap of $179.05 million, a PE ratio of -5.72 and a beta of 0.81.

Hedge Funds Weigh In On MediWound

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its stake in MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock valued at $193,000 after purchasing an additional 739 shares during the last quarter. Russell Investments Group Ltd. increased its position in MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 1,162 shares during the period. Barclays PLC increased its position in MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 1,249 shares during the period. R Squared Ltd acquired a new position in MediWound in the 4th quarter valued at approximately $32,000. Finally, Bank of America Corp DE increased its position in MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 2,178 shares during the period. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.